Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

A mosaic activating mutation in AKT1 associated with the Proteus syndrome.

Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG.

N Engl J Med. 2011 Aug 18;365(7):611-9. doi: 10.1056/NEJMoa1104017. Epub 2011 Jul 27.

2.

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P.

N Engl J Med. 2011 Jun 2;364(22):2119-27. doi: 10.1056/NEJMoa1012863.

3.

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".

Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM.

J Transl Med. 2011 Mar 26;9:32. doi: 10.1186/1479-5876-9-32.

4.

Cardiac magnetic resonance appearance of myocarditis caused by high dose IL-2: similarities to community-acquired myocarditis.

Ingkanisorn WP, Paterson DI, Calvo KR, Rosing DR, Schwartzentruber DJ, Fuisz AR, Arai AE.

J Cardiovasc Magn Reson. 2006;8(2):353-60.

PMID:
16669178
5.

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.

Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T Jr, Takeshita K, Inghirami G, McGaughey D, Watson TM, Snow S, Kubovic P, Ferraro M, Jones E, Jaffe ES, Schwartzentruber DJ, Danforth D, Sherry R, Kass E, Van Waes C, Reynolds CW, Kwak LJ.

Clin Lymphoma. 2005 Jun;6(1):61-4. No abstract available.

PMID:
15989711
6.

Gastrointestinal perforations associated with interleukin-2 administration.

Heimann DM, Schwartzentruber DJ.

J Immunother. 2004 May-Jun;27(3):254-8. Review.

PMID:
15076143
7.

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.

J Immunother. 2003 Sep-Oct;26(5):385-93.

8.

Cancer vaccines.

Muehlbauer PM, Schwartzentruber DJ.

Semin Oncol Nurs. 2003 Aug;19(3):206-16. Review.

PMID:
12962010
9.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA.

J Clin Oncol. 2003 Aug 15;21(16):3127-32.

10.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.

Clin Cancer Res. 2003 Aug 1;9(8):2973-80.

11.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA.

N Engl J Med. 2003 Jul 31;349(5):427-34.

12.

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.

Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

J Immunother. 2003 Jul-Aug;26(4):349-56.

13.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. Epub 2003 Jun 25.

14.

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE.

Hum Gene Ther. 2003 May 20;14(8):709-14.

15.

Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP; Pediatric Oncology Group.

J Clin Oncol. 2003 Apr 15;21(8):1574-80.

PMID:
12697883
16.

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.

17.

Principles for the surgical management of patients with Proteus syndrome and patients with overgrowth not meeting Proteus criteria.

Lublin M, Schwartzentruber DJ, Lukish J, Chester C, Biesecker LG, Newman KD.

J Pediatr Surg. 2002 Jul;37(7):1013-20. Review.

PMID:
12077761
18.

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA.

J Immunother. 2002 May-Jun;25(3):243-51.

19.

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ.

J Immunother. 2002 Jan-Feb;25(1):82-7.

20.

Clinical pathways for managing patients receiving interleukin 2.

Mavroukakis SA, Muehlbauer PM, White RL Jr, Schwartzentruber DJ.

Clin J Oncol Nurs. 2001 Sep-Oct;5(5):207-17. Review.

PMID:
11905416
21.

Hepatic abscess in patients with chronic granulomatous disease.

Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, Shawker T, Choyke P, Kleiner DE, Schwartzentruber DJ, Chang R, DeCarlo ES, Holland SM.

Ann Surg. 2002 Mar;235(3):383-91.

22.

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA.

J Clin Oncol. 2002 Jan 1;20(1):142-52.

23.

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC.

J Exp Med. 2001 Dec 17;194(12):1731-41.

24.

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA.

J Immunother. 2001 Jul-Aug;24(4):363-73.

PMID:
11565838
25.

Guidelines for the safe administration of high-dose interleukin-2.

Schwartzentruber DJ.

J Immunother. 2001 Jul-Aug;24(4):287-93. Review.

PMID:
11565830
26.

High-dose interleukin-2 is an intensive treatment regardless of the venue of administration.

Schwartzentruber DJ.

Cancer J. 2001 Mar-Apr;7(2):103-4. No abstract available.

PMID:
11324761
27.

Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.

Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ.

J Immunother. 2000 May-Jun;23(3):387-92.

PMID:
10838668
28.

MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.

Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, Diamond RA, Robbins PF, Schwartzentruber DJ, Rosenberg SA.

Cancer Res. 1999 Dec 15;59(24):6230-8.

29.

Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient.

Orenstein JM, Feinberg M, Yoder C, Schrager L, Mican JM, Schwartzentruber DJ, Davey RT Jr, Walker RE, Falloon J, Kovacs JA, Miller KD, Fox C, Metcalf JA, Masur H, Polis MA.

AIDS. 1999 Nov 12;13(16):2219-29.

PMID:
10563707
30.

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE.

J Immunol. 1999 Aug 1;163(3):1690-5.

31.

Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?

Hurst R, White DE, Heiss J, Lee DS, Rosenberg SA, Schwartzentruber DJ.

J Immunother. 1999 Jul;22(4):356-62.

PMID:
10404437
32.

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM.

J Clin Oncol. 1999 Mar;17(3):968-75.

PMID:
10071291
33.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE.

J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900.

34.

A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.

Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA.

J Immunol. 1998 Oct 1;161(7):3598-606.

35.

Splenectomy in a child with chronic Mycobacterium avium complex infection and splenic sequestration.

Kaufman HL, Roden M, Nathanson D, Basso TM, Schwartzentruber DJ, Holland SM.

J Pediatr Surg. 1998 May;33(5):761-3.

PMID:
9607493
36.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE.

Nat Med. 1998 Mar;4(3):321-7.

37.

Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.

Cohen OJ, Vaccarezza M, Lam GK, Baird BF, Wildt K, Murphy PM, Zimmerman PA, Nutman TB, Fox CH, Hoover S, Adelsberger J, Baseler M, Arthos J, Davey RT Jr, Dewar RL, Metcalf J, Schwartzentruber DJ, Orenstein JM, Buchbinder S, Saah AJ, Detels R, Phair J, Rinaldo C, Margolick JB, Pantaleo G, Fauci AS.

J Clin Invest. 1997 Sep 15;100(6):1581-9.

38.

Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.

Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ.

Cancer J Sci Am. 1996 Sep-Oct;2(5):263-72.

PMID:
9166543
39.

Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.

Mueller BU, Sei S, Anderson B, Luzuriaga K, Farley M, Venzon DJ, Tudor-Williams G, Schwartzentruber DJ, Fox C, Sullivan JL, Pizzo PA.

J Pediatr. 1996 Sep;129(3):410-8.

PMID:
8804331
40.

Dynamics of virus versus host interaction in children with human immunodeficiency virus type 1 infection.

Sei S, Akiyoshi H, Bernard J, Venzon DJ, Fox CH, Schwartzentruber DJ, Anderson BD, Kopp JB, Mueller BU, Pizzo PA.

J Infect Dis. 1996 Jun;173(6):1485-90.

PMID:
8648226
41.

Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, Roche K, Schwartzentruber DJ, Fox CH, Fauci AS.

N Engl J Med. 1996 May 9;334(19):1222-30.

42.

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, Marincola FM, Parkinson DR, Schwartzentruber DJ, Topalian SL, Yang JC, Rosenberg SA.

Cancer J Sci Am. 1996 Mar-Apr;2(2):91-8.

PMID:
9166506
43.

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.

Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):272-8.

PMID:
8680655
44.
45.

Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review.

Ettinghausen SE, Schwartzentruber DJ, Sindelar WF.

J Clin Gastroenterol. 1995 Jul;21(1):48-60. Review.

PMID:
7560834
46.

Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals.

Cohen OJ, Pantaleo G, Schwartzentruber DJ, Graziosi C, Vaccarezza M, Fauci AS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S6-14. Review. Erratum in: J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):210.

PMID:
8595512
47.

CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.

Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ.

Cancer Immunol Immunother. 1995 Jan;40(1):1-9. Erratum in: Cancer Immunol Immunother 1995 Sep;41(3):201.

PMID:
7828162
48.

Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.

White RL Jr, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, Rosenberg SA.

Cancer. 1994 Dec 15;74(12):3212-22.

PMID:
7982185
49.

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE.

J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66.

PMID:
8028037
50.

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI, et al.

J Clin Oncol. 1994 Aug;12(8):1572-6.

PMID:
8040669

Supplemental Content

Loading ...
Support Center